Allakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory ...
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated cash outlook as reported by ...
Allakos reports Q4 EPS 0c, consensus (18c)
Allakos (ALLK) ended the fourth quarter of 2024 with $80.8M in cash, cash equivalents and investments.Light Up your Portfolio with Spark:Easily ...